Richard M Burwick, Sigal Yawetz, Kathryn E Stephenson, Ai-Ris Y Collier, Pritha Sen, Brian G Blackburn, E Milunka Kojic, Adi Hirshberg, Jose F Suarez, Magdalena E Sobieszczyk, Kristen M Marks, Shawn Mazur, Cecilia Big, Oriol Manuel, Gregory Morlin, Suzanne J Rose, Mariam Naqvi, Ilona T Goldfarb, Adam DeZure, Laura Telep, Susanna K Tan, Yang Zhao, Tom Hahambis, Jason Hindman, Anand P Chokkalingam, Christoph Carter, Moupali Das, Anu O Osinusi, Diana M Brainard, Tilly A Varughese, Olga Kovalenko, Matthew D Sims, Samit Desai, Geeta Swamy, Jeanne S Sheffield, Rebecca Zash, William R Short
BACKGROUND: Remdesivir is efficacious for severe coronavirus disease 2019 (COVID-19) in adults, but data in pregnant women are limited. We describe outcomes in the first 86 pregnant women with severe COVID-19 who were treated with remdesivir. METHODS: The reported data span 21 March to 16 June 2020 for hospitalized pregnant women with polymerase chain reaction-confirmed severe acute respiratory syndrome coronavirus 2 infection and room air oxygen saturation ≤94% whose clinicians requested remdesivir through the compassionate use program...
December 6, 2021: Clinical Infectious Diseases